Mr. David Levine reports

DRI HEALTHCARE TRUST PROVIDES UPDATE ON NATPARA ROYALTY

Based on its continuing review of its royalty entitlement on Natpara, DRI Healthcare Trust has concluded that the issues that led to the 2019 recall of Natpara in the United States are likely to remain unresolved for the foreseeable future while royalties on European and rest-of-world sales are expected to continue in the near term. There have been no commercial sales of Natpara in the United States since the product's recall in 2019.

The Natpara royalty is paid on global sales of Natpara and is subject to an aggregate cap on royalty receipts of $125-million, of which $85.9-million (U.S.) has been collected by DRI and its predecessor funds as of Sept. 30, 2022. DRI is reviewing its options with respect to the Natpara royalty. DRI will provide further updates as they become available.

About DRI Healthcare Trust

DRI Healthcare is managed by DRI Capital Inc., the pioneer in global pharmaceutical royalty monetization with a more-than-30-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since DRI Healthcare's founding in 1989, DRI Capital has deployed more than $2-billion (U.S.), acquiring more than 60 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.

We seek Safe Harbor.